Thank you, Mr. Chair.
I want to thank all of you for being here today under what we recognize as very difficult circumstances. I'm impressed by the consistency in all of your presentations over the essentially collateral vulnerabilities that you're dealing with while the focus is on the pandemic. I think that's a message that really is very important for this committee to consider. Thank you for that.
I want to start with Mr. Belliveau, about vaccines.
Just a week ago, your organization released a press release calling on governments to make the COVID-19 vaccine licensing agreements public, noting that these agreements remain cloaked in secrecy despite unprecedented levels of public funding. To what extent, if at all, is your organization concerned that these licensing agreements with pharmaceutical companies could complicate efforts to deliver COVID-19 vaccines to vulnerable populations in developing countries?